GILEAD SCIENCES, INC. (GILD)
Biological Products, (No Diagnostic Substances) · Biological Products, (No Diagnostic Substances) · NASDAQ
$143.44
+3.25%
Investingg Score
66.1 / 100
Hold
Business overview
- Operating margin stands at 34% based on the provided data.
- Free cash flow margin is recorded at 32.1%.
These strong margins show that the core operations are efficient at converting revenue into profit and cash.
Financial health
- Balance sheet pillar score is reported at 43.
- Risk pillar score is listed at 100.
While the low balance sheet score points to underlying debt or coverage uncertainties, the maximum risk score suggests limited near-term volatility triggers from the dataset.
- Gross Margin
- Data unavailable
- Operating Margin
- 34.0%
- Current Ratio
- 1.6x
- Debt / Equity
- 0.97
- Free Cash Flow (TTM)
- $9.5B
- Interest Coverage
- Data unavailable
Valuation
- Price-to-sales ratio is 6.01.
- Free cash flow yield is 5.3%.
- Valuation pillar score is 63.
These valuation metrics present a moderate pricing picture relative to sales and cash generation, though lack of P/E data introduces some valuation uncertainty.
- P/E (TTM)
- Data unavailable
- Forward P/E
- Data unavailable
- Price / Sales
- 6.0x
- EV / EBITDA
- Data unavailable
- FCF Yield
- 5.3%
Key risks
- Balance sheet score is relatively low at 43, indicating potential financial structure vulnerabilities.
- Growth score of 46 highlights that top-line expansion remains subdued.
- RSI of 71.57 suggests the stock may be entering overbought territory technically.
Market cap $178.0B · data as of 2026-08-18
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze GILD with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.